The activating p.Val600Glu mutation in BRAF is considered the main important alteration detectable in melanoma samples due to the high occurrence in up to 95% of BRAF-mutant melanomas [17] and to the improvement of survival in response to BRAF-inhibitor treatments in patients affected by metastatic melanoma harboring this mutation [18]. This evidence concerns the gene BRAF and melanoma.